Previous 10 | Next 10 |
Cellect Biotechnology (NASDAQ: APOP ) +43% after reverse split & ADS ratio change. More news on: Cellect Biotechnology Ltd., PDS Biotechnology Corporation, Genocea Biosciences, Inc., Stocks on the move, Read more ...
Genocea Biosciences ( GNCA ) Q3 results : Revenues: $0; R&D Expense: $6.8M (+6.2%); SG&A: $2.7M (-34.1%); Operating loss: ($9.6M) (+8.6%); Net loss: ($7.5M) (+3.8%); loss/share: ($0.28) (+61.1%); Quick Assets: $46.6M (+76.5%). More news on: Genocea Biosciences, Inc., Healthcare st...
Genocea Biosciences (NASDAQ: GNCA ): Q3 GAAP EPS of -$0.28 beats by $0.18 . More news on: Genocea Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2019 financial results and corporate update conference call and live audio webcast...
The following slide deck was published by Genocea Biosciences, Inc. in conjunction with this Read more ...
Additional p ositive GEN-009 c linical i mmunogenicity d ata d riven by ATLAS™ to be p resented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Genocea Bio...
CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present at two leading healthcare confer...
Genocea Biosciences, Inc. (GNCA) Q2 2019 Earnings Conference Call July 25, 2019, 08:30 ET Company Participants Daniel Ferry - LifeSci Advisors William Clark - President, CEO & Director Diantha Duvall - CFO Thomas Davis - Chief Medical Officer Conference Call Participants...
Genocea Biosciences (NASDAQ: GNCA ): Q2 GAAP EPS of -$0.42 beats by $0.24 . More news on: Genocea Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009; Plans to present additional GEN-009 immunogenicity data at ESMO 2019 Conference call today at 8:30 am ET CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (...
News, Short Squeeze, Breakout and More Instantly...
Genocea Biosciences Inc. Company Name:
GNCA Stock Symbol:
NASDAQ Market:
Genocea Biosciences Inc. Website:
Genocea Biosciences Inc Ordinary Shares (GNCA) is expected to report for Q4 2022